Abstract: (64)Cu-NOTA-TRC105-Fab cleared rapidly through the kidneys, which enabled noninvasive PET imaging of the aorta with enhanced contrast and showed increased angiogenesis (CD105 expression) during AAA. (64)Cu-NOTA-TRC105-Fab PET may potentially be used for future diagnosis and prognosis of AAA.
Introduction
Abdominal Aortic Aneurysm (AAA) is a progressive condition involving the weakening and dilation of the aortic wall, posing a significant risk of catastrophic rupture. Current clinical management relies heavily on measuring the maximum aortic diameter to assess rupture risk. However, size alone is an insufficient predictor, as small aneurysms can rupture while larger ones may remain stable. Angiogenesis—the formation of new microvessels—is a critical biological process driving AAA progression and wall instability. This study investigates the use of a novel PET tracer targeting CD105 (endoglin), a marker of active angiogenesis, to noninvasively visualize AAA activity.
Methods
The researchers developed a PET imaging probe by engineering a Fab fragment from the anti-CD105 monoclonal antibody TRC105. The smaller size of the Fab fragment (~50–55 kDa) compared to the full antibody facilitates faster blood clearance, thereby enhancing imaging contrast. The fragment was conjugated with a NOTA chelator and radiolabeled with Copper-64 (<sup>64</sup>Cu). The probe's efficacy was tested in a BALB/c mouse model of AAA induced by topical calcium phosphate application. Longitudinal micro-PET/CT imaging was performed at 5 and 12 days post-induction, with specificity confirmed through blocking studies using unlabeled TRC105.
Results
The <sup>64</sup>Cu-NOTA-TRC105-Fab probe demonstrated high sensitivity and specificity for imaging AAA. PET scans revealed significant tracer accumulation in the aneurysmal region as early as 30 minutes post-injection, with high contrast maintained for up to 24 hours.
Quantitative analysis showed that tracer uptake was significantly higher during the early expansion phase (Day 5: 9.5 ± 0.4 %ID/g) compared to the later stage (Day 12: 7.2 ± 1.4 %ID/g). The use of the Fab fragment resulted in excellent aorta-to-muscle ratios, peaking at approximately 8.0, which allowed for clear differentiation of the diseased tissue from the background.
The specificity of the probe was confirmed by the "blocking" group, where pre-injection of unlabeled antibody significantly reduced the PET signal. Furthermore, the probe cleared rapidly through the kidneys, minimizing interference from abdominal background noise—a common issue with other tracers like <sup>18</sup>F-FDG.
Discussion
This study highlights the potential of CD105-targeted PET imaging to provide a biological assessment of AAA activity beyond simple anatomical measurements. The peak in tracer uptake at Day 5 suggests that angiogenesis is most intense during early rapid expansion in this model. While the mouse model differs from the chronic progression of human AAA, the high contrast and specificity achieved with the <sup>64</sup>Cu-NOTA-TRC105-Fab probe suggest it could be a valuable tool for future clinical diagnosis and prognosis, potentially identifying high-risk aneurysms that require intervention regardless of their size.
Summary updated